Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK010 + PD-1 Antibody + Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
NCT07318636Phase 1Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK010 in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events up to 1 year and Dose Limiting Toxicities up to 21 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
NK010
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07318636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318636.